HOOK Stock Overview
A clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HOOKIPA Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.74 |
| 52 Week High | US$1.13 |
| 52 Week Low | US$0.41 |
| Beta | 0.75 |
| 1 Month Change | -13.45% |
| 3 Month Change | 3.41% |
| 1 Year Change | -28.51% |
| 3 Year Change | -92.13% |
| 5 Year Change | -89.88% |
| Change since IPO | -94.69% |
Recent News & Updates
Recent updates
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth
Apr 28
Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts
Mar 24Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023
Aug 11HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%
May 16Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
Apr 26Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues
Nov 19HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy
Jul 25Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts
May 18Hookipa: Speculative Biotech With Key Catalysts In 2022
Mar 29Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?
Oct 01Checking Back In On HOOKIPA Pharma
Jun 22Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers
Jun 08Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?
Apr 19If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns
Mar 15Shareholder Returns
| HOOK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.2% | 0.02% | 1.2% |
| 1Y | -28.5% | 6.7% | 20.6% |
Return vs Industry: HOOK underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: HOOK underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| HOOK volatility | |
|---|---|
| HOOK Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: HOOK's share price has been volatile over the past 3 months.
Volatility Over Time: HOOK's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 165 | Joern Aldag | www.hookipapharma.com |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial.
HOOKIPA Pharma Inc. Fundamentals Summary
| HOOK fundamental statistics | |
|---|---|
| Market cap | US$77.38m |
| Earnings (TTM) | -US$47.52m |
| Revenue (TTM) | US$53.55m |
1.4x
P/S Ratio-1.5x
P/E RatioIs HOOK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOOK income statement (TTM) | |
|---|---|
| Revenue | US$53.55m |
| Cost of Revenue | US$84.31m |
| Gross Profit | -US$30.76m |
| Other Expenses | US$16.76m |
| Earnings | -US$47.52m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | -57.44% |
| Net Profit Margin | -88.73% |
| Debt/Equity Ratio | 1.1% |
How did HOOK perform over the long term?
See historical performance and comparison